$84.8 M

ARMP Mkt cap, 18-Oct-2021
Armata Pharmaceuticals Net income (Q1, 2021)-5.5 M
Armata Pharmaceuticals EBIT (Q1, 2021)-5.4 M
Armata Pharmaceuticals Cash, 31-Mar-202122.5 M
Armata Pharmaceuticals EV74.7 M
Get notified regarding key financial metrics and revenue changes at Armata PharmaceuticalsLearn more
Banner background

Armata Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

409.0k

R&D expense

5.8m4.0m5.7m2.9m4.9m9.8m14.4m

General and administrative expense

6.9m6.4m8.4m7.6m5.7m9.3m8.0m

Operating expense total

12.7m10.4m14.1m10.5m10.6m19.1m22.4m

EBIT

(14.1m)(10.2m)(23.4m)(16.2m)(12.5m)(19.8m)(21.6m)

EBIT margin, %

(3450%)

Interest expense

Interest income

6.0k96.0k28.0k

Pre tax profit

(589.0k)(19.4m)(14.1m)(12.4m)(19.5m)(22.2m)

Income tax expense

(73.0k)(556.0k)(1.3m)(328.0k)

Net Income

23.1m(516.0k)(18.8m)(12.8m)(12.1m)(19.5m)(22.2m)

Armata Pharmaceuticals Balance Sheet

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

16.4m12.6m9.8m16.6m14.4m11.7m6.2m7.1m4.0m2.2m9.0m7.7m8.2m5.8m4.5m5.5m13.2m8.7m24.2m19.8m15.9m22.5m

Accounts Receivable

12.0k136.0k27.0k40.0k14.0k18.0k24.0k15.0k

Prepaid Expenses

280.0k526.0k448.0k413.0k512.0k785.0k566.0k576.0k570.0k343.0k282.0k264.0k537.0k322.0k615.0k407.0k1.0m652.0k567.0k898.0k804.0k459.0k

Current Assets

16.7m13.2m10.3m17.0m14.9m12.6m6.8m7.7m4.6m2.6m9.2m8.0m8.7m6.1m5.1m5.9m14.2m9.9m25.8m20.7m17.0m24.0m

PP&E

356.0k1.1m1.3m1.2m1.1m1.2m1.2m1.2m1.2m982.0k909.0k847.0k727.0k678.0k591.0k420.0k3.4m2.5m2.0m2.0m2.0m2.1m

Goodwill

4.3m7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m3.5m3.5m3.5m3.5m3.5m3.5m

Total Assets

34.4m34.7m31.9m38.6m36.4m34.1m28.3m29.3m26.0m14.3m15.1m13.8m14.4m11.7m10.6m9.6m34.9m29.3m44.1m49.5m45.7m52.8m

Accounts Payable

879.0k1.4m1.8m1.5m1.4m1.2m2.0m2.2m2.2m1.1m1.9m949.0k810.0k682.0k714.0k1.8m1.8m1.3m1.4m1.5m1.9m1.8m

Dividends Payable

131.0k368.0k368.0k970.0k953.0k38.0k38.0k38.0k

Short-term debt

598.0k606.0k305.0k1.3m1.3m1.4m405.0k1.4m1.6m

Current Liabilities

879.0k1.7m2.5m2.1m2.2m2.3m2.7m3.3m3.2m2.9m3.7m2.5m1.8m2.0m2.5m3.6m5.6m5.0m6.4m5.2m7.1m5.0m

Long-term debt

2.4m1.9m1.2m11.5m10.9m10.8m

Non-Current Liabilities

57.6m49.6m23.4m

Total Debt

598.0k606.0k305.0k3.7m3.2m2.6m11.9m12.3m12.4m

Total Liabilities

58.5m51.3m25.9m39.4m19.3m7.5m5.7m7.8m7.8m7.7m5.2m4.0m3.1m3.4m3.8m4.7m12.3m11.2m10.6m19.8m21.1m18.8m

Common Stock

1.8m1.9m1.9m2.8m57.0k59.0k59.0k111.0k111.0k165.0k85.0k93.0k165.0k165.0k165.0k328.0k99.0k99.0k186.0k186.0k187.0k249.0k

Preferred Stock

89.0k1.7m

Additional Paid-in Capital

367.0m360.9m362.0m370.6m378.8m375.9m374.5m390.9m390.0m391.1m400.9m401.5m408.5m408.6m408.7m414.6m168.5m171.0m195.9m196.8m197.5m219.0m

Retained Earnings

(394.8m)(382.5m)(361.3m)(376.5m)(365.7m)(360.3m)(365.6m)(369.5m)(371.9m)(384.6m)(391.1m)(391.9m)(397.3m)(400.4m)(402.0m)(409.9m)(146.0m)(152.9m)(162.6m)(167.3m)(173.1m)(185.2m)

Total Equity

(24.1m)(17.9m)4.4m(3.1m)13.1m15.7m8.9m21.5m18.2m6.6m9.9m9.8m11.3m8.3m6.9m5.0m22.6m18.1m33.5m29.6m24.6m34.0m

Financial Leverage

-1.4 x-1.9 x7.3 x-12.6 x2.8 x2.2 x3.2 x1.4 x1.4 x2.2 x1.5 x1.4 x1.3 x1.4 x1.5 x1.9 x1.5 x1.6 x1.3 x1.7 x1.9 x1.6 x

Armata Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

23.1m(516.0k)(18.8m)(12.8m)(12.1m)(19.5m)(22.2m)

Depreciation and Amortization

158.0k330.0k369.0k374.0k389.0k1.1m

Accounts Receivable

(92.0k)(25.0k)100.0k(467.0k)

Accounts Payable

(977.0k)296.0k298.0k(838.0k)343.0k(1.4m)544.0k

Cash From Operating Activities

(12.6m)(9.8m)(10.6m)(9.2m)(9.4m)(15.6m)(18.3m)

Purchases of PP&E

(1.2m)(210.0k)(279.0k)(58.0k)(44.0k)(224.0k)(824.0k)

Cash From Investing Activities

(1.2m)(210.0k)(279.0k)(58.0k)(44.0k)2.9m(824.0k)

Dividends Paid

(80.0k)

Cash From Financing Activities

12.8m7.2m8.7m12.5m9.0m23.2m

Net Change in Cash

(13.8m)2.8m(3.7m)(579.0k)3.0m(3.7m)4.1m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(10.1m)2.6m23.8m(14.5m)(3.7m)1.7m(3.1m)(7.0m)(9.3m)(3.2m)(9.7m)(10.5m)(3.1m)(6.2m)(7.8m)(3.6m)(7.9m)(14.9m)(5.1m)(9.8m)(15.6m)(5.5m)

Depreciation and Amortization

18.0k101.0k82.0k66.0k132.0k240.0k81.0k173.0k268.0k93.0k185.0k278.0k97.0k193.0k291.0k108.0k683.0k1.0m295.0k575.0k281.0k

Accounts Receivable

(4.0k)(128.0k)(19.0k)100.0k100.0k60.0k111.0k107.0k101.0k10.0k12.0k12.0k

Accounts Payable

(1.3m)(675.0k)(305.0k)158.0k181.0k(11.0k)436.0k573.0k482.0k(520.0k)(189.0k)(845.0k)(416.0k)28.0k218.0k453.0k(599.0k)(1.2m)(195.0k)234.0k492.0k(409.0k)

Cash From Operating Activities

(3.7m)(6.7m)(9.4m)(2.3m)(5.0m)(7.5m)(3.1m)(6.0m)(9.1m)(3.3m)(6.2m)(6.8m)(3.5m)(5.7m)(7.0m)(2.6m)(8.3m)(12.9m)(4.2m)(8.1m)(12.0m)(5.5m)

Purchases of PP&E

(229.0k)(1.1m)(1.2m)(35.0k)(44.0k)(160.0k)(112.0k)(237.0k)(266.0k)(5.0k)(7.0k)(40.0k)(31.0k)(41.0k)(7.0k)(268.0k)(203.0k)(104.0k)(377.0k)(458.0k)(298.0k)

Cash From Investing Activities

(229.0k)(1.1m)(1.2m)(35.0k)(44.0k)(160.0k)(112.0k)(237.0k)(266.0k)(5.0k)(7.0k)(40.0k)(31.0k)(41.0k)(7.0k)2.7m2.8m(104.0k)(377.0k)(458.0k)(298.0k)

Short-term Borrowings

(205.0k)(205.0k)(510.0k)

Dividends Paid

(63.0k)(80.0k)

Cash From Financing Activities

12.4m12.8m12.8m4.0m4.0m(205.0k)9.5m8.9m6.6m6.4m6.4m5.0k9.0m9.0m22.4m22.7m22.8m18.6m

Net Change in Cash

(3.9m)(7.8m)(10.6m)10.0m7.8m5.2m(3.2m)(2.2m)(5.4m)(3.5m)3.3m2.0m3.1m666.0k(633.0k)(2.6m)3.4m(1.1m)18.1m14.3m10.4m12.8m

Armata Pharmaceuticals Ratios

USDQ1, 2014

Financial Leverage

-1.4 x